Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$MNTM Reverse merger PR out Friday with bannermidstream.com ! 3 rev. producing companies in there portf. including pinnaclefrac.com and capstoneleasing.com Pres. Jay Puchir was recently CFO of $ZEST wit a 52wk high of 1.33. Watch for 8K! Chart has lots of room!!!
Agreed Mr. PickthePenny... -- All indicators show a Filing will come within the Four Days that is required .... so will be watching into next week. -- This is so much under the Radar it may start slow and then take off once this gets out . It is Current , in NV SOS , and has some good structure so while others should be cautious of the pumps out there that the SEC has been suspending and revoking .... -- $MNTM, has some real good positive structure to move on and will bring folks into it going into October .... --
$MNTM -- Under Radar -- Merger is Merger -- Current -- SEC Filings are all current -- Low Float -- This has all the bells and whistles of a larger mover ..
Small float that is why it was so easy to run MNTM yesterday.
MNTM Market Cap Market Cap 1,169,925 09/26/2019 Authorized Shares 200,000,000 09/03/2019 Outstanding Shares 55,710,702 09/03/2019 Restricted Not Available Unrestricted Not Available Held at DTC Not Available Float 15,425,625 10/21/2015 Par Value No Par Value
Bids moving up. Look at historical trading. There is NO front loading here so anyone that is selling into the .03s ~ .04s are not making profit. Silly.
MNTM Market Cap Market Cap 1,169,925 09/26/2019 Authorized Shares 200,000,000 09/03/2019 Outstanding Shares 55,710,702 09/03/2019 Restricted Not Available Unrestricted Not Available Held at DTC Not Available Float 15,425,625 10/21/2015 Par Value No Par Value
Looks like it is being accumulated. Could see .10 short-term imho. Aside from the Merger News I also find this in the PR interesting as well:
Mount Tam is advancing its lead asset, TAM-01, toward an Investigational New Drug (IND) application with the FDA and has already completed non-GLP pre-clinical development. The lead indication for TAM-01 is expected to be the treatment of SLE. Mount Tam is also advancing follow-on compounds through the discovery process and is looking at a broad range of disease areas where novel mTOR inhibitors have been shown to have the potential to address unmet need.
$WNTM .04 added! Already hit .0799 today on huge MERGER news. Peeps need to read that PR in detail to see what else the company also has going on.
News Out -- Mount Tam and Banner Midstream Sign Merger Agreement
September 27, 2019 09:00 ET | Source: Mount Tam Biotechnologies Inc. BURLINGTON, VT, Sept. 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Mount Tam Biotechnologies, Inc. (OTC: MNTM) ("Mount Tam"), announced that it has signed a Merger Agreement with Banner Midstream Corp. ("Banner Midstream”). The Merger Agreement was signed on September 26, 2019. The merger is expected to close by the middle of Q4 2019 pending various approvals and the meeting of certain closing conditions by both parties. At closing, Banner Midstream’s stockholders will own a majority controlling interest in the public entity.
As part of the transaction, Mount Tam and its secured debt holders have agreed that the holders will take possession of the biotechnology assets and other Mount Tam obligations in lieu of the amounts due in the secured debt instruments.
Richard Marshak, Chief Executive Officer and Director of Mount Tam, said, "We view this merger as an important and positive step for stockholders of Mount Tam, providing them a stake in an established company with proven leadership, solid revenues and an excellent strategic vision for growth. We look forward to working with Banner Midstream to meet all the closing conditions and finalize the merger.”
"We are excited for our company’s stockholders, management, employees, and contractors to have the opportunity to operate within a public company structure," said Jay Puchir, Banner Midstream’s President and Principal Financial Officer. "Banner Midstream plans to continue its growth through acquisition and intends to uplist to a national exchange when the company is eligible."
About Banner Midstream Corp:
Based in Frisco, TX, Banner Midstream Corp. (“Banner Midstream”) is a fully integrated oil field services company. The Company was formed in 2018 as a reaction to explosive customer demand for oilfield services and transportation in Texas and surrounding states of Louisiana, Oklahoma and New Mexico (the “Territory”). Its focus is on commercializing its services and becoming the main source of transportation services and equipment rental to major customers in the Permian Basin, Barnett Shale, Eagle Ford Shale, Haynesville-Bossier Shale, and the Marcellus Shale. Banner Midstream believes that its services make it unique and could potentially lead to a larger portion of the market share of existing and future operations in the oilfield services sector of the Texas region and nearby areas. Its strategy centers on taking advantage of a market made up of many sole proprietorship or small private companies with minimal access to capital.
As of its December 31, 2018 fiscal year-end, Banner Midstream has two wholly-owned subsidiaries as its main operating segments: Pinnacle Frac Transport LLC (“Pinnacle Frac”), and Capstone Equipment Leasing LLC (“Capstone”). Pinnacle Frac commenced operations in May 2018 and is engaged in the business of providing transportation of frac sand and logistics services to major hydraulic fracturing and drilling operators in the domestic United States. Capstone commenced operations in October 2018 and is engaged in the business of procuring and financing equipment to various oilfield transportation services contractors.
Mount Tam Biotechnologies was established to develop, optimize and bring to market novel pharmaceutical products to improve the health and well-being of patients suffering from a range of serious disease states where there is significant unmet need. Its most advanced compound is being developed to treat systemic lupus erythematosus (SLE).
Mount Tam has partnered with the world-renowned Buck Institute for Research on Aging through a worldwide exclusive licensing and collaboration agreement. The assets are highly target-specific polyketides--a class of compounds with a successful track record with the FDA drug approval process. The assets are supported by an impressive intellectual property portfolio consisting of worldwide patents and patent applications including composition of matter, manufacturing and therapeutic area applications.
Mount Tam is advancing its lead asset, TAM-01, toward an Investigational New Drug (IND) application with the FDA and has already completed non-GLP pre-clinical development. The lead indication for TAM-01 is expected to be the treatment of SLE. Mount Tam is also advancing follow-on compounds through the discovery process and is looking at a broad range of disease areas where novel mTOR inhibitors have been shown to have the potential to address unmet need.
For more information, please visit www.mounttambiotech.com.
Forward-Looking Statements:
This release contains forward-looking statements, including, without limitation, statements concerning our business, possible or assumed future results of operations, potential business combinations, and the results from such business combinations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Further, it is possible that the transaction with Banner Midstream does not materialize and the merger is not consummated, as it is subject to various closing conditions and approvals, including regulatory approval. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We expressly disclaim any obligation or intention to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law.
For more information please contact:
MOUNT TAM BIOTECHNOLOGIES, INC.: Jim Stapleton (425) 214-4079 jim@mounttambiotech.com
BANNER MIDSTREAM CORP: Richard Horgan (800) 203-5610 rhorgan@bannermidstream.com
News Out -- Mount Tam and Banner Midstream Sign Merger Agreement
September 27, 2019 09:00 ET | Source: Mount Tam Biotechnologies Inc. BURLINGTON, VT, Sept. 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Mount Tam Biotechnologies, Inc. (OTC: MNTM) ("Mount Tam"), announced that it has signed a Merger Agreement with Banner Midstream Corp. ("Banner Midstream”). The Merger Agreement was signed on September 26, 2019. The merger is expected to close by the middle of Q4 2019 pending various approvals and the meeting of certain closing conditions by both parties. At closing, Banner Midstream’s stockholders will own a majority controlling interest in the public entity.
As part of the transaction, Mount Tam and its secured debt holders have agreed that the holders will take possession of the biotechnology assets and other Mount Tam obligations in lieu of the amounts due in the secured debt instruments.
Richard Marshak, Chief Executive Officer and Director of Mount Tam, said, "We view this merger as an important and positive step for stockholders of Mount Tam, providing them a stake in an established company with proven leadership, solid revenues and an excellent strategic vision for growth. We look forward to working with Banner Midstream to meet all the closing conditions and finalize the merger.”
"We are excited for our company’s stockholders, management, employees, and contractors to have the opportunity to operate within a public company structure," said Jay Puchir, Banner Midstream’s President and Principal Financial Officer. "Banner Midstream plans to continue its growth through acquisition and intends to uplist to a national exchange when the company is eligible."
About Banner Midstream Corp:
Based in Frisco, TX, Banner Midstream Corp. (“Banner Midstream”) is a fully integrated oil field services company. The Company was formed in 2018 as a reaction to explosive customer demand for oilfield services and transportation in Texas and surrounding states of Louisiana, Oklahoma and New Mexico (the “Territory”). Its focus is on commercializing its services and becoming the main source of transportation services and equipment rental to major customers in the Permian Basin, Barnett Shale, Eagle Ford Shale, Haynesville-Bossier Shale, and the Marcellus Shale. Banner Midstream believes that its services make it unique and could potentially lead to a larger portion of the market share of existing and future operations in the oilfield services sector of the Texas region and nearby areas. Its strategy centers on taking advantage of a market made up of many sole proprietorship or small private companies with minimal access to capital.
As of its December 31, 2018 fiscal year-end, Banner Midstream has two wholly-owned subsidiaries as its main operating segments: Pinnacle Frac Transport LLC (“Pinnacle Frac”), and Capstone Equipment Leasing LLC (“Capstone”). Pinnacle Frac commenced operations in May 2018 and is engaged in the business of providing transportation of frac sand and logistics services to major hydraulic fracturing and drilling operators in the domestic United States. Capstone commenced operations in October 2018 and is engaged in the business of procuring and financing equipment to various oilfield transportation services contractors.
Mount Tam Biotechnologies was established to develop, optimize and bring to market novel pharmaceutical products to improve the health and well-being of patients suffering from a range of serious disease states where there is significant unmet need. Its most advanced compound is being developed to treat systemic lupus erythematosus (SLE).
Mount Tam has partnered with the world-renowned Buck Institute for Research on Aging through a worldwide exclusive licensing and collaboration agreement. The assets are highly target-specific polyketides--a class of compounds with a successful track record with the FDA drug approval process. The assets are supported by an impressive intellectual property portfolio consisting of worldwide patents and patent applications including composition of matter, manufacturing and therapeutic area applications.
Mount Tam is advancing its lead asset, TAM-01, toward an Investigational New Drug (IND) application with the FDA and has already completed non-GLP pre-clinical development. The lead indication for TAM-01 is expected to be the treatment of SLE. Mount Tam is also advancing follow-on compounds through the discovery process and is looking at a broad range of disease areas where novel mTOR inhibitors have been shown to have the potential to address unmet need.
For more information, please visit www.mounttambiotech.com.
Forward-Looking Statements:
This release contains forward-looking statements, including, without limitation, statements concerning our business, possible or assumed future results of operations, potential business combinations, and the results from such business combinations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Further, it is possible that the transaction with Banner Midstream does not materialize and the merger is not consummated, as it is subject to various closing conditions and approvals, including regulatory approval. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We expressly disclaim any obligation or intention to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law.
For more information please contact:
MOUNT TAM BIOTECHNOLOGIES, INC.: Jim Stapleton (425) 214-4079 jim@mounttambiotech.com
BANNER MIDSTREAM CORP: Richard Horgan (800) 203-5610 rhorgan@bannermidstream.com
Ignore previous posts. I got wrong end of the stick. Got it confirmed: ARJ bought out the subsidiary and took it private, leaving MNTM parent company and its new Therapeutics company (with the Buck Institute licenses) with nice influx of cash to continue with their biotech research.
$MNTM Before ARJ Consulting bought Mount Tam Delaware, the medical licenses were transferred out to a newly created, corporation, Mount Tam Therapeutics. So Andrew Garnock got a nice clean subsidiary with some NOLs and tax credits for $410k -- which begs the question what he plans to do with it?
One thought is that he will use it to expand his own nano CBD venture, given his immense success with PharmaCam/Cronos. Not sure if it could tie in with Vrus just yet, but you never know.
Only 55 million shares, and lots of it owned by insiders. Tantalizing possibilities.
- - -
On October 18, 2018, the “Company” and Mount Tam Biotechnologies, Inc., a Delaware corporation, its wholly-owned Delaware subsidiary (“Mount Tam Delaware”), entered into a stock purchase agreement (the “SPA”) with ARJ Consulting, LLC, a New York limited liability company (the “Buyer”), pursuant to which the Company sold 100% of the capital stock in and of Mount Tam Delaware to the Buyer (the “Sale Transaction”).
Prior to the Sale Transaction, the Company caused Mount Tam to transfer certain assets, including the Buck Institute License Agreement, that Mount Tam Delaware was holding to another wholly-owned subsidiary of the Company, Mount Tam Therapeutics, Inc., a newly formed (October 2018) Delaware corporation. At the time of the Sale Transaction Mount Tam possessed certain Net Operating Losses and tax credits. Pursuant to the terms of the SPA, the Buyer purchased Mount Tam for a purchase price of $410,000.
More price movement. Be interesting to see full picture of ARJ’s involvement in Vrus when S1 appears in next week or two. Garnock clearly acquired nice clean Mount Tam Delaware subsidiary for a reason too.
Correction: Looks like $VRUS investor Andrew Garnock spent $410K for a wholly owned subsidiary called Mount Tam Delaware, and any of the main company's biotech projects were spun off into another new subsidiary called Mount Tam Therapeutics.
On October 18, 2018, the “Company” and Mount Tam, its wholly-owned subsidiary, entered into a stock purchase agreement (the “SPA”) with ARJ Consulting, LLC, a New York limited liability company (the “Buyer”), pursuant to which the Company sold 100% of the capital stock in and of Mount Tam to the Buyer (the “Sale Transaction”). Prior to the Sale Transaction, the Company caused Mount Tam to transfer certain assets, including the Buck Institute License Agreement, that Mount Tam was holding to another wholly-owned subsidiary of the Company, Mount Tam Therapeutics, Inc., a Delaware corporation. At the time of the Sale Transaction Mount Tam possessed certain Net Operating Losses and tax credits. Pursuant to the terms of the SPA, the Buyer purchased Mount Tam for a purchase price of $410,000.
Unique URL to the upcoming webcast of the Mount Tam Biotechnologies (OTC: MNTM) presentation from the 2017 BIO CEO & Investor Conference to be held at the Waldorf Astoria (February 13-14, 2017, New York, NY):
1). MOUNT TAM BIOTECHNOLOGIES (OTC: MNTM) WEBCAST URL:
News 
Market Data 
Discover 
